CRISPR Therapeutics AG $CRSP Shares Acquired by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 104.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,550 shares of the company’s stock after buying an additional 24,316 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in CRISPR Therapeutics were worth $2,262,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRSP. Royal Bank of Canada raised its stake in CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after acquiring an additional 31,392 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth about $861,000. Woodline Partners LP boosted its position in CRISPR Therapeutics by 34.3% in the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after buying an additional 34,883 shares during the last quarter. Prudential Financial Inc. acquired a new position in CRISPR Therapeutics in the 2nd quarter worth approximately $237,000. Finally, Invesco Ltd. raised its position in CRISPR Therapeutics by 138.4% during the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock worth $3,242,000 after buying an additional 38,691 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $54.92 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm has a market capitalization of $5.30 billion, a P/E ratio of -8.83 and a beta of 1.74. The stock’s fifty day moving average is $52.72 and its two-hundred day moving average is $53.04. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million during the quarter. On average, research analysts anticipate that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on CRSP. Sanford C. Bernstein lifted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research report on Thursday, June 11th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group set a $80.00 price objective on CRISPR Therapeutics in a report on Friday, June 12th. Finally, Truist Financial raised CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

Insider Activity

In related news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.